TABLE 4.
Reasons for discontinuation of PHP-Mel treatment
| Reason for discontinuation | Randomized to PHP | After crossover to PHP | Total PHP patients |
|---|---|---|---|
| (N = 42) [n (%)] | (N = 28) [n (%)] | (N = 70) [n (%)] | |
| Death | 3 (4.8) | 1 (3.6) | 4 (4.3) |
| Disease progression | 12 (28.6) | 8 (28.6) | 20 (28.6) |
| Hepatic progression | 3 (9.5) | 1 (3.6) | 4 (7.1) |
| Extrahepatic progression | 8 (19.0) | 7 (25.0) | 15 (21.4) |
| Adverse events | 15 (35.7) | 9 (32.1) | 24 (34.3) |
| Platelet count decreased | 6 (14.3) | 6 (21.4) | 12 (17.1) |
| Neutrophil count decreased | 3 (7.1) | 2 (7.1) | 5 (7.1) |
| Blood bilirubin increased | 3 (7.1) | 1 (3.6) | 4 (5.7) |
| Patient decision | 1 (2.4) | 0 | 1 (1.4) |
| Investigator’s opinion | 7 (16.7) | 2 (7.1) | 9 (12.9) |
| Lost to follow-up | 0 | 0 | 0 |
| Completed four cycles of therapy and no clinical indication to continue | 2 (4.8) | 3 (10.7) | 5 (7.1) |
| Completed six cycles of PHP therapy or equivalent of BAC (twelve 3-week cycles) | 1 (2.4) | 1 (3.6) | 2 (2.9) |
| Other | 2 (4.8) | 4 (14.3) | 6 (8.6) |
PHP Percutaneous hepatic perfusion, BAC best alternative care